AstraZeneca PLC AZN NYSE

AstraZeneca PLC (AZN) reported total assets of $114.07B and total liabilities of $65.36B for fiscal year 2025, resulting in total equity of $48.72B.

The company held $5.74B in cash and short-term investments. Total debt stood at $29.7B, with net debt of $23.99B. The Debt-to-Equity (D/E) ratio was 0.61 (moderate).

Current ratio is 0.94, which may signal tight short-term liquidity. Interest coverage is 8.1x (strong).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (94/100) — Total assets $114.07B and equity $48.72B support the company's competitive scale
• VALUE (29/100) — Debt-to-Equity 0.61 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 64/100 with 4/7 criteria passed.

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%

RHHBY

Roche Holding AG

$51.02

+0.65%

MRK

Merck & Co., Inc.

$119.96

-0.16%

NVS

Novartis AG

$153.38

-0.71%

AMGN

Amgen Inc.

$350.95

+0.32%

GILD

Gilead Sciences, Inc.

$140.45

+1.02%